Chugai Pharmaceutical Co., Ltd. Web Site ... 07/30/2008 FDA Advisory Committee Votes in Favor to Recommend Approval of Actemra ®, a Humanized Anti-Human ...

Chugai Pharmaceutical Co., Ltd. and F. Hoffmann-La Roche Ltd. announced today that the humanized anti-human IL-6 (interleukin-6) receptor monoclonal antibody, Actemra(R) [ generic ...

... Humanized Anti-Human IL-6 Receptor Monoclonal Antibody, Filed for Rheumatoid Arthritis in Europe   (Chugai)   03-Dec-2007 "Actemra®," a Humanized Anti-Human IL ...

Osamu Nagayama (hereafter, "Chugai")] announced today that the humanized anti-human interleukin-6 (IL-6) receptor monoclonal antibody, Actemra® 200mg for Intravenous Infusion ...

humanized antibody Molecular medicine A recombinant DNA product which ? non-human ... Chugai Announces Japanese Phase III Trial Data Demonstrates Efficacy ... by JCN Newswires

Chugai also is developing Actemra (tocilizumab), a new humanized anti-human interleukin-6 (IL-6) receptor monoclonal antibody whose novel mechanism of action provides a new and ...

Free Online Library: Chugai Announces Japanese Phase III Trial Data Demonstrates Efficacy of 'Actemra(R),' a Humanized Anti-Human IL-6 Receptor Monoclonal Antibody, on Rheumatoid ...

The Chugai Humanized Anti-Human Recombinant Interleukin-6 Monoclonal Antibody (CHARISMA) study evaluated the safety and efficacy of repeated infusions of tocilizumab alone and in ...

Chugai Pharma USA LLC is a research-based, global pharmaceutical company that discovers ... MRA (tocilizumab) is a humanized monoclonal antibody against the human ...

San Francisco, CA, USA) Multiple myeloma, non-Hodgkin lymphoma: Phase I : SK2: IgG1: Humanized: Mus musculus: IL-6: Chugai pharmaceuticals Co. Ltd. (Japan) / F.

Chugai Announces Japanese Phase III Trial Data Demonstrates Efficacy of 'Actemra(R),' a Humanized Anti-Human IL-6 Receptor Monoclonal Antibody, on Rheumatoid Arthritis Patients

Chugai Announces Japanese Phase III Trial Data Demonstrates Efficacy of 'Actemra(R),' a Humanized Anti-Human IL-6 Receptor Monoclonal Antibody, on Rheumatoid Arthritis Patients

Avastin, a humanized anti- vascular endothelial growth factor monoclonal antibody; Tarceva that inhibits the activation of human epiderm... Chugai Pharmaceutical Co., Ltd. engages ...

Chugai Announces Japanese Phase III Trial Data Demonstrates Efficacy of 'Actemra(R),' a Humanized Anti-Human IL-6 Receptor Monoclonal Antibody, on Rheumatoid Arthritis Patients

Chugai Announces Japanese Phase III Trial Data Demonstrates Efficacy of 'Actemra(R),' a Humanized Anti-Human IL-6 Receptor Monoclonal Antibody, on Rheumatoid Arthritis Patients

Chugai Pharmaceutical Co., Ltd. and F. Hoffmann-La Roche Ltd. announced today that the humanized anti-human IL-6 (interleukin-6) receptor monoclonal antibody, Actemra(R) [ generic ...

Tokyo, Apr 19, 2007 (JCN Newswire) - Chugai Pharmaceutical Co., Ltd. announced today that bevacizumab (genetical recombination), a humanized anti-VEGF (Vascular Endothelial Growth ...

Chugai Pharmaceutical Files New Drug Application for Anti-tumor Agent Bevacizumab. by ... Bevacizumab, which is a humanized anti-VEFG monoclonal antibody, is currently marketed in ...

Chugai Pharma USA ... Humanized antibody against the IL-6 receptor. In Phase I studies in the US and Phase II in ...

Chugai Announces Japanese Phase III Trial Data Demonstrates Efficacy ... by JCN Newswires ... A Humanized Antibody Against CD40 (SGN-40) is Well Tolerated and Active in Non-Hodgkin's ...

Chugai, the Japanese subsidiary of Roche, is developing a humanized anti-interleukin (IL)-6 receptor monoclonal antibody MRA for the potential treatment of multiple myeloma ...

tocilizumab: Actemra: AI: monoclonal antibody: humanised anti-IL-6 receptor monoclonal antibody: sJIA: 3 : 2010: Chugai: R1594 ocrelizumab: NME: monoclonal antibody: humanized anti-CD20 monoclonal ...

Selection of therapeutic antibodies successfully humanized by AERES on ... Chugai Pharmaceuticals (Japan)

Tokyo - Chugai Pharmaceutical Co., Ltd [Head Office: Chuo-ku, Tokyo; President Osamu Nagayama (hereinafter, Chugai)] announced that the humanized anti-human IL-6 (interleukin-6 ...

Roche and Chugai to jointly develop and promote Chugai?s promising new Rheumatoid ... MRA is a humanized anti-human IL-6 receptor monoclonal antibody and with its novel ...

... University of Tokushima, Tokushima, and Fuji-Gotemba Research Laboratory, Chugai ... Effect of humanized anti-HM1.24 MoAb on hematopoietic progenitor cells. To determine the ...

Chugai Announces Japanese Phase III Trial Data Demonstrates Efficacy of 'Actemra(R),' a Humanized Anti-Human IL-6 Receptor Monoclonal Antibody, on Rheumatoid Arthritis Patients

Find out key developments for CHUGAI PHARMACEUTICAL CO LTD 4519.T at Reuters.com ... Ltd., which is owned by Roche, regarding the manufacturing of "Actemra", a Humanized Anti ...

Actemra, the first antibody drug (humanized monoclonal antibody) originating from Japan, was created by Chugai in collaboration with Osaka University, utilizing genetic recombinant ...

Humanized Anti-HM1.24 Antibody Mediates Myeloma Cell Cytotoxicity That Is Enhanced by ... University of Tokushima, Tokushima, and Fuji-Gotemba Research Laboratory, Chugai ...